By: Kairos Ventures On: May 3, 2022 In: Foldax, Portfolio News

Foldax announced that the first patients have been enrolled in the Drugs Controller General of India (DCGI)-approved clinical trial...

Read more
By: Kairos Ventures On: February 28, 2022 In: Foldax, Portfolio News

Foldax has announced the presentation of results from the first animal study of its transcatheter valve from the TRIA...

Read more
By: Kairos Ventures On: December 21, 2021 In: Foldax, Portfolio News

Foldax announced publication of the first clinical results for its TRIA™ biopolymer heart valve - the first polymer valve...

Read more
By: Kairos Ventures On: September 28, 2021 In: Foldax, Portfolio News

Foldax® announced completion of enrollment in the U.S. early feasibility study of the TRIA™ surgical aortic heart valve. The...

Read more
By: Kairos Ventures On: May 25, 2021 In: Foldax, Portfolio News

Foldax announced the successful first-in-human use of its biopolymer Tria™ heart valve in surgically replacing a diseased mitral valve....

Read more
By: Kairos Ventures On: March 8, 2021 In: Foldax, Portfolio News

Foldax is looking to reinvent every aspect of the heart valve—from material, to design, to manufacturing. Foldax is working...

Read more
By: Kairos Ventures On: January 28, 2021 In: Foldax, Portfolio News

Foldax has announced the publication of a research paper in Advanced NanoBiomed Research that concluded that its LifePolymer biopolymer...

Read more
By: Kairos Ventures On: December 14, 2020 In: Foldax, Portfolio News

Foldax®, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval for the company to...

Read more
By: Kairos Ventures On: October 28, 2020 In: Foldax, Portfolio News

The Salt Lake City, UT-based company won FDA approval to expand a clinical study of the Tria surgical aortic...

Read more
By: Kairos Ventures On: October 26, 2020 In: Foldax

Foldax announced that the U.S. Food and Drug Administration (FDA) has granted approval to expand the U.S. clinical study...

Read more